PARP inhibitors alone and in combinations are demonstrating potential in castration-resistant prostate cancer, but questions about survival benefit, toxicities, and efficacy remain to be answered.
Pei-Chun McGregor, MD, discusses where future research with androgen deprivation therapy-associated adverse events is headed, and called for multidisciplinary care for patients receiving this approach.
Atish D. Choudhury, MD, PhD, details the advances in metastatic prostate cancer in light of updated analyses from several clinical trials and forthcoming research in the field.
Richard (Rick) JaeBong Lee, MD, PhD, discusses the differences between second-generation targeted antiandrogens and highlights potential factors to consider in terms of selection.
David J. Einstein, MD, discusses newer imaging techniques and overall progress in the treatment of patients with nonmetastatic hormone-sensitive prostate cancer.
A supplemental new drug application has been submitted to the FDA for the approval of apalutamide (Erleada) for use as a treatment of patients with metastatic castration-sensitive prostate cancer.
The FDA has granted a priority review designation to a new drug application for darolutamide for use as a treatment for patients with nonmetastatic castration-resistant prostate cancer.
Implementation of an integrated practice model, in which in-house and outside referrals are available, has enabled Garden State Urology to continue to provide patients with high standards of care while maintaining the familiarity of a community style clinic.
For the urologist who feels overworked and overstretched, paradigm-shifting advances may represent an opportunity to stave off burnout, more effectively use clinical acumen gained over the years, and maintain practice engagement.
Leonard G. Gomella, MD, underscores the need for genetic testing in prostate cancer, sheds light on important biomarkers in the space, and explains how these tests are helping oncologists facilitate a precision medicine approach.